Eagle Ridge Investment Management Has $321,000 Stock Holdings in Sanofi (NASDAQ:SNY)

Eagle Ridge Investment Management boosted its position in Sanofi (NASDAQ:SNY) by 3.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,571 shares of the company’s stock after buying an additional 203 shares during the period. Eagle Ridge Investment Management’s holdings in Sanofi were worth $321,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Magnetar Financial LLC raised its stake in shares of Sanofi by 1,153.1% in the second quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after purchasing an additional 2,306,286 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares in the last quarter. Mondrian Investment Partners LTD lifted its holdings in shares of Sanofi by 43.1% in the first quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after purchasing an additional 1,190,141 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Sanofi by 3,440.6% during the first quarter. BNP Paribas Financial Markets now owns 1,033,549 shares of the company’s stock valued at $50,230,000 after buying an additional 1,004,358 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on SNY. Argus raised their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Price Performance

SNY opened at $52.05 on Friday. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The firm has a 50-day moving average of $56.12 and a 200 day moving average of $51.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $132.08 billion, a P/E ratio of 28.29, a PEG ratio of 1.40 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. During the same quarter last year, the business posted $0.95 EPS. Sanofi’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, research analysts expect that Sanofi will post 4.23 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.